— Specialty pharmaceutical company AcelRx Pharmaceuticals (NASDAQ: ACRX) reported fourth quarter 2019 loss of $0.18 per share vs. expected loss of $0.20 per share.
— Revenue was $0.48 million vs. $1.01 million expected.
— AcelRx also announced today about its acquisition of Tetraphase Pharmaceuticals for $14.4 million. This stock for stock deal is expected to close in the second quarter of 2020.
— AcelRx and Tetraphase have also entered into a co-promotion agreement, which will benefit both the teams in promoting multiple products, leveraging each company’s customer relationships, and creating efficiencies among commercial teams prior to the closing of the merger.
— AcelRx expects to achieve its previously communicated target of 465 REMS-certified facilities and formulary approvals by the end of 2020.
— The company expects quarterly combined R&D and SG&A expense in 2020 to range from $10 million to $13 million, depending on the quarter. This estimate includes approximately $1 million of non-cash stock-based compensation per quarter.
— ACRX stock was down more than 10% in the pre-market trading session.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
